Observational Study in Patients Who Underwent an Haploidentical Transplantation With T-repleted Bone Marrow

N/ATerminatedNCT02049424

Istituto Clinico Humanitas9 enrolled

Overview

Outcome evaluation in patients who underwent transplantation with T-repleted bone marrow after post-transplantation cyclophosphamide

Patients who underwent transplantation with T-repleted bone marrow haploidentical transplantation will be analyzed considering toxicity incidence (GVHD, infective complications, graft-failure incidence and TRM)and efficacy variables (Overall Survival, Progression Free Survival and Relapse incidence)

Study Type

OBSERVATIONAL

Enrollment

Conditions

Hematologic Malignancy

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: \- patients affected by hematologic neoplasia who underwent a haploidentical transplantation (2-3 mismatches) from a familiar donor, with non-ex vivo manipulated bone marrow and post-transplantation cyclophosphamide Exclusion Criteria: * ex vivo manipulated bone marrow transplantation * use of antilymphocyte serum during conditioning

Locations (1)

Istituto Clinico Humanitas

Rozzano, MI, Italy

Outcomes

Primary Outcomes

toxicity evaluation

Chronic and acute GVHD, infectious complications, graft failure, TRM

Time frame: 1 year

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.